Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Regorafenib + Bicarbonate in CRC Liver Mets
NCT05894837Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
serplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05894837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894837.